Visible Genomics, a Chicago-area genetics testing company and founders of a non-invasive genetic eye test that determines a patient’s likelihood of contracting Age-Related Macular Degeneration (AMD), announced today that it has appointed Dr. Barry Eiden, Dr. Steven Ferrucci, Dr. Alan Glazier, and Dr. Treacy Adamo to its board of clinical advisors.
CHICAGO, IL; October 2020 - Visible Genomics, a Chicago-area genetics testing company and founders of a non-invasive genetic eye test that determines a patient’s likelihood of contracting Age-Related Macular Degeneration (AMD), announced today that it has appointed Dr. Barry Eiden, Dr. Steven Ferrucci, Dr. Alan Glazier, and Dr. Treacy Adamo to its board of clinical advisors.
“We are pleased to welcome Barry, Steve, Alan, and Treacy as our new independent team of clinical advisors to the Visible Genomics board, and we especially value their range of medical optometry research and experience,” said Frank Adamo, Founder and CEO of Visible Genomics. “They join Visible Genomics at an exciting time as we launch a non-invasive genetic eye test for AMD. Our new board will be instrumental in building deeper relationships with doctors as well as patients, fulfilling our purpose of helping people keep their vision healthy.”
The Visible Genomics board had recently evaluated its composition to ensure it includes the appropriate skills, experience, and perspective necessary to drive growth for its new product and services.
“I appreciate Visible Genomics’ collaborative approach and I believe the new appointments will be a significant asset to the company,” said Dr. Barry Eiden who uses the Visible Genomics testing system in his own practice, adding, “The results provided with earlier intervention of testing for AMD lead to a better prognosis and outcome. We’re now able to create a personalized patient management plan, and take the proper steps by delaying disease onset or slowing disease progression.”
Chief of Optometry at the Sepulveda VA Ambulatory Care Center, Dr. Steven Ferrucci remarked that “By knowing a patients genetic risk for advancing AMD, the doctor can better educate the patient and individualize a treatment plan for that specific patient.”
Traditionally, patients who were at risk of developing AMD or progressing to advanced stages of AMD have had no advance awareness of its probability, and were diagnosed only after severe symptoms had surfaced. Visible Genomics created the genetic assessment test specifically for AMD to help doctors and their patients take preventative and proactive care of their vision. The clinically-validated saliva-based test combines a person’s genetic status, ocular findings, and demographic and lifestyle characteristics to deliver a comprehensive and clinically actionable risk assessment. This assessment determines the AMD patient’s progression risk of developing advanced AMD, and predicts the lifetime risk for those with a family member with AMD.
For more information visit Visible Genomics and watch the AMD Protocol Webinar with Dr. Treacy Adamo, or call 855-MYEYES7 (855-693-9377).
About Dr. Barry Eiden OD, FAAO
Dr. Barry Eiden is president and medical director of North Suburban Vision Consultants, Ltd., a multi-specialty group practice. He is also president and founder of the International Keratoconus Academy of Eye Care Professionals, an organization providing education and research to eye care professionals. Additionally, Dr. Eiden is co-founder and president of EyeVis Eye and Vision Research Institute, which is dedicated to the clinical research and development of technologies in the field of eye care. Dr. Eiden is an assistant clinical professor in the Department of Ophthalmology, Cornea and Contact Lens Service of the University of Illinois at Chicago Medical Center, and an adjunct faculty member of the Indiana, Illinois, Salus, and UMSL Colleges of Optometry.
About Dr. Steven Ferrucci OD, FAAO
Dr. Steven Ferrucci, is Chief of Optometry at the Sepulveda VA Ambulatory Care Center and Nursing Home. He is also the Residency Director at his site, and a Professor at the Southern California College of Optometry at Marshall B. Ketchum University. Dr. Ferrucci has lectured extensively with a special interest in Diabetes, Diabetic Eye Disease, Age-Related Macular Degeneration, Fluorescein Angiography, and OCT. Currently, he serves on the Editorial Board for Review of Optometry, Optometry Times, and Modern Optometry. He was also recently recognized as one of the top 250 Innovators in Optometry by Primary Care Optometry News. He is an active member in the American Optometric Association and the California Optometric Association, as well as a fellow in both the American Academy of Optometry and the Optometric Retinal Society.
About Dr. Alan Glazier OD, FAAO
Dr. Alan Glazier is the founder and visionary behind ODs on Facebook and ODsOnFB.com, the eye care industry’s largest and most highly engaged eye care organization with over 41,500 members. He also is the founder of Shady Grove Eye and Vision Care in Rockville, Maryland, and is a partner and business development executive in Keplr Vision, enabling Optometrists with mature practices a medical model legacy exit. Dr. Glazier is a Board Member of the New England College of Optometry, and has been peer-selected as one of the 50 most influential optometrists in the country.
About Dr. Treacy Adamo OD, FAAO
Dr. Treacy Adamo is the Owner and Medical Director of Hinsdale Advanced Eye Care, fellow of the American Academy of Optometry, and past president of the Illinois state chapter of the American Academy of Optometry. She volunteers for the National Board of Examiners in Optometry as an examiner, is the Assistant Chief of Optometry at the Adam Benjamin Jr. VA outpatient clinic in Crown Point, Indiana, and serves as an adjunct clinical instructor for the Illinois College of Optometry.
About Visible Genomics
Based in the Chicago area, Visible Genomics is the creator and manufacturer of a new non-invasive genetic eye test that determines a patient’s likelihood of developing Age-Related Macular Degeneration (AMD), a disease that causes blindness in up to 11 million Americans, with an additional 20 million people who are at risk with a family history of the disease. The Visible Genomics solution empowers the patient and healthcare professional to make informed clinical and lifestyle decisions together to help slow or prevent AMD. For more information, visit Visible Genomics.
Caption: Visible Genomics has appointed four new members to its board of clinical advisors: from left, Dr. Barry Eiden; Dr. Alan Glazier; Dr. Steven Ferrucci; and Dr. Treacy Adamo.
